These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 27466354)

  • 1. Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma.
    Buondonno I; Gazzano E; Jean SR; Audrito V; Kopecka J; Fanelli M; Salaroglio IC; Costamagna C; Roato I; Mungo E; Hattinger CM; Deaglio S; Kelley SO; Serra M; Riganti C
    Mol Cancer Ther; 2016 Nov; 15(11):2640-2652. PubMed ID: 27466354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts.
    Gazzano E; Buondonno I; Marengo A; Rolando B; Chegaev K; Kopecka J; Saponara S; Sorge M; Hattinger CM; Gasco A; Fruttero R; Brancaccio M; Serra M; Stella B; Fattal E; Arpicco S; Riganti C
    Cancer Lett; 2019 Aug; 456():29-39. PubMed ID: 31047947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABCA1/ABCB1 Ratio Determines Chemo- and Immune-Sensitivity in Human Osteosarcoma.
    Belisario DC; Akman M; Godel M; Campani V; Patrizio MP; Scotti L; Hattinger CM; De Rosa G; Donadelli M; Serra M; Kopecka J; Riganti C
    Cells; 2020 Mar; 9(3):. PubMed ID: 32155954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression.
    Sugiu K; Tazawa H; Hasei J; Yamakawa Y; Omori T; Komatsubara T; Mochizuki Y; Kondo H; Osaki S; Fujiwara T; Yoshida A; Kunisada T; Ueda K; Urata Y; Kagawa S; Ozaki T; Fujiwara T
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):513-524. PubMed ID: 34114067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pioglitazone modulates doxorubicin resistance in a in vivo model of drug resistant osteosarcoma xenograft.
    Natarajan A; Ramachandran B; Gopisetty G; Jayavelu S; Sundersingh S; Rajkumar T
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Feb; 394(2):361-371. PubMed ID: 33015747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma.
    Godel M; Morena D; Ananthanarayanan P; Buondonno I; Ferrero G; Hattinger CM; Di Nicolantonio F; Serra M; Taulli R; Cordero F; Riganti C; Kopecka J
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32599901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1® can Overcome Drug Resistance in Osteosarcoma.
    Fanelli M; Hattinger CM; Vella S; Tavanti E; Michelacci F; Gudeman B; Barnett D; Picci P; Serra M
    Curr Cancer Drug Targets; 2016; 16(3):261-74. PubMed ID: 26548759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High expression of ABCG2 is associated with chemotherapy resistance of osteosarcoma.
    Shu H; Yuan B; Huang Y; Wang L; He B; Sun Q; Sun L
    J Orthop Surg Res; 2021 Jan; 16(1):85. PubMed ID: 33509236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rhein reverses doxorubicin resistance in SMMC-7721 liver cancer cells by inhibiting energy metabolism and inducing mitochondrial permeability transition pore opening.
    Wu L; Cao K; Ni Z; Wang S; Li W; Liu X; Chen Z
    Biofactors; 2019 Jan; 45(1):85-96. PubMed ID: 30496631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells.
    Takeshita H; Kusuzaki K; Ashihara T; Gebhardt MC; Mankin HJ; Hirasawa Y
    J Bone Joint Surg Am; 2000 Jul; 82-A(7):963-9. PubMed ID: 10901311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance.
    Liu T; Li Z; Zhang Q; De Amorim Bernstein K; Lozano-Calderon S; Choy E; Hornicek FJ; Duan Z
    Oncotarget; 2016 Dec; 7(50):83502-83513. PubMed ID: 27835872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VCPA, a novel synthetic derivative of α-tocopheryl succinate, sensitizes human gastric cancer to doxorubicin-induced apoptosis via ROS-dependent mitochondrial dysfunction.
    Wu H; Liu S; Gong J; Liu J; Zhang Q; Leng X; Zhang N; Li Y
    Cancer Lett; 2017 May; 393():22-32. PubMed ID: 28216375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-221 Upregulates the Expression of P-gp and Bcl-2 by Activating the Stat3 Pathway to Promote Doxorubicin Resistance in Osteosarcoma Cells.
    Liu Y; Liu X; Yang S
    Biol Pharm Bull; 2021 Jun; 44(6):861-868. PubMed ID: 33828027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polydatin inhibits proliferation and promotes apoptosis of doxorubicin-resistant osteosarcoma through LncRNA TUG1 mediated suppression of Akt signaling.
    Hu T; Fei Z; Su H; Xie R; Chen L
    Toxicol Appl Pharmacol; 2019 May; 371():55-62. PubMed ID: 30974157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic Effects of a Smac Mimetic with Doxorubicin Against Human Osteosarcoma.
    Kamata E; Kawamoto T; Ueha T; Hara H; Fukase N; Minoda M; Morishita M; Takemori T; Fujiwara S; Nishida K; Kuroda R; Kurosaka M; Akisue T
    Anticancer Res; 2017 Nov; 37(11):6097-6106. PubMed ID: 29061790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA Sox2OT-V7 promotes doxorubicin-induced autophagy and chemoresistance in osteosarcoma via tumor-suppressive miR-142/miR-22.
    Zhu K; Yuan Y; Wen J; Chen D; Zhu W; Ouyang Z; Wang W
    Aging (Albany NY); 2020 Apr; 12(8):6644-6666. PubMed ID: 32302291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. circ_0002060 Enhances Doxorubicin Resistance in Osteosarcoma by Regulating the miR-198/ABCB1 Axis.
    Ji Y; Liu J; Zhu W; Ji J
    Cancer Biother Radiopharm; 2023 Nov; 38(9):585-595. PubMed ID: 33351694
    [No Abstract]   [Full Text] [Related]  

  • 18. Targeted inhibition of T-cell factor activity promotes syndecan-2 expression and sensitization to doxorubicin in osteosarcoma cells and bone tumors in mice.
    Dieudonné FX; Marion A; Marie PJ; Modrowski D
    J Bone Miner Res; 2012 Oct; 27(10):2118-29. PubMed ID: 22550000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Folate-mediated mitochondrial targeting with doxorubicin-polyrotaxane nanoparticles overcomes multidrug resistance.
    Wang H; Yin H; Yan F; Sun M; Du L; Peng W; Li Q; Feng Y; Zhou Y
    Oncotarget; 2015 Feb; 6(5):2827-42. PubMed ID: 25605018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel derivative of doxorubicin, AD198, inhibits canine transitional cell carcinoma and osteosarcoma cells in vitro.
    Rathore K; Cekanova M
    Drug Des Devel Ther; 2015; 9():5323-35. PubMed ID: 26451087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.